As humans, we are allowed a lot of room to make mistakes. After all, this is pretty much how we learn and grow over time, right? Now, while that’s accurate, we, at the same time, can’t really skirt past some obligations in play, a notable one being our obligation to move forward under all circumstances. […]

What You Should Know: – DarioHealth Corp., a provider of global digital therapeutics (DTx), announced it has entered into a $30M multi-year, strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement will help accelerate commercial adoption of Dario’s full suite of digital therapeutics and drive the expansion of digital health […]

Later this year, Fulcrum Therapeutics will launch a Phase III study of losmapimod in people with facioscapulohumeral muscular dystrophy (FSHD), hoping to become the company to produce the first approved drug aimed at one of the most common forms of the disease. Fulcrum’s Phase III REACH trial of losmapimod in this indication, builds on the Phase IIb ReDUX4 study […]